ABVC BioPharma financials
$1.04−0.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $509.6K | $152.4K | $969.8K | $355.8K |
| Gross profit | $0.00 | $508.8K | -$149.6K | $683.4K | $350.7K |
| Gross margin | — | 99.9% | −98.1% | 70.5% | 98.6% |
| Operating income | -$7.2M | -$4.7M | -$6.8M | -$15.2M | -$11.7M |
| Net income | -$7.9M | -$4.9M | -$7.8M | -$16.4M | -$12.8M |
| Net margin | — | −962.1% | −5109.3% | −1693.5% | −3608.5% |
| Diluted EPS | $-0.39 | $-0.42 | $-1.80 | $-5.19 | $-5.10 |
| EBITDA | -$7.1M | -$4.7M | -$6.7M | -$15.1M | -$11.7M |
| Operating cash flow | -$3.0M | -$1.8M | -$4.2M | -$7.4M | -$7.2M |
| Free cash flow | -$3.0M | -$1.8M | -$4.2M | -$7.5M | -$7.3M |
| Diluted shares | 20.1M | 11.7M | 4.3M | 3.2M | 2.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $681.5K | $248.4K | $60.2K | $85.3K | $5.8M |
| Short-term investments | $64.4K | $64.7K | $79.3K | $75.8K | $108.1K |
| Total debt | $755.5K | $840.3K | $1.8M | $1.9M | $1.6M |
| Total assets | $21.1M | $7.5M | $7.8M | $9.6M | $13.7M |
| Total liabilities | $7.8M | $6.8M | $6.5M | $6.3M | $4.8M |
| Shareholders' equity | $13.3M | $724.0K | $1.3M | $3.2M | $8.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology